Rhythm Pharmaceuticals

OverviewSuggest Edit

Rhythm Pharmaceuticals is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
TypePublic
Founded2008
HQBoston, US
Websiterhythmtx.com

Latest Updates

Employees (est.) (Nov 2017)22(+23%)
Share Price (Mar 2020)$14 (-3%)

Key People/Management at Rhythm Pharmaceuticals

Nithya Desikan

Nithya Desikan

Chief Commercial Officer
Simon D. Kelner

Simon D. Kelner

Chief Human Resources Officer
Hunter Smith

Hunter Smith

Chief Financial Officer
Murray Stewart

Murray Stewart

Chief Medical Officer
David Meeker

David Meeker

Chairman
Keith M. Gottesdiener

Keith M. Gottesdiener

Chief Executive Officer
Show more

Rhythm Pharmaceuticals Office Locations

Rhythm Pharmaceuticals has an office in Boston
Boston, US (HQ)
222 Berkeley St 12th floor
Show all (1)

Rhythm Pharmaceuticals Financials and Metrics

Rhythm Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(10.0m)

EBIT (Q3, 2017)

(8.3m)

Market capitalization (27-Mar-2020)

618.6m

Closing stock price (27-Mar-2020)

14.0

Cash (30-Sept-2017)

27.9m
Rhythm Pharmaceuticals's current market capitalization is $618.6 m.
Annual
USDFY, 2015FY, 2016

General and administrative expense

3.4m6.3m

R&D expense

7.1m19.6m

Operating expense total

10.6m25.9m

EBIT

(10.6m)(25.9m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

982.0k2.3m

R&D expense

5.4m6.0m

Operating expense total

6.4m8.3m

EBIT

(6.4m)(8.3m)
Annual
USDFY, 2015FY, 2016

Cash

34.9m6.5m

Prepaid Expenses

623.0k638.0k

Current Assets

35.5m11.2m

PP&E

17.0k930.0k
Quarterly
USDQ2, 2017Q3, 2017

Cash

8.7m27.9m

Prepaid Expenses

722.0k1.6m

Current Assets

18.5m32.0m

PP&E

822.0k845.0k
Annual
USDFY, 2015FY, 2016

Net Income

(11.1m)(25.9m)

Depreciation and Amortization

144.0k

Accounts Payable

893.0k467.0k

Cash From Operating Activities

(7.0m)(23.2m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1m)(17.5m)(13.2m)(23.2m)

Depreciation and Amortization

33.0k89.0k108.0k163.0k

Accounts Payable

882.0k(335.0k)(602.0k)830.0k

Cash From Operating Activities

(12.6m)(17.0m)(13.2m)(21.6m)
USDY, 2017

Financial Leverage

-0.7 x
Show all financial metrics

Rhythm Pharmaceuticals Online and Social Media Presence

Embed Graph

Rhythm Pharmaceuticals News and Updates

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

-- On track to complete rolling NDA submission to the FDA for setmelanotide in POMC and LEPR deficiency obesities in the first quarter of 2020 -- -- Granted orphan drug designation by the European Medicines Agency for setmelanotide in Alström syndrome --

Rhythm Pharmaceuticals stock falls on news CEO is leaving

Shares of Rhythm Pharmaceuticals Inc. were down 3% in trading on Tuesday, the day after the company announced that president and CEO Keith Gottesdiener plans to step down. Gottesdiener, who became CEO at Rhythm in 2011, will stay in his role until the drugmaker completes its new drug application su…

Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

-- Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities -- -- Added Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and Enrolling Patients --

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the pricing of its public offering of 8,108,108…

Rhythm Pharmaceuticals to Provide an Update on Genetic Sequencing Efforts and Expansion of Phase 2 Basket Study with Four Additional Rare MC4R Pathway-driven Disorders

-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications ---- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant opportunity for setmelanotide across new indications ---- Rhythm to host and webcast R&D breakfast event…

Rhythm Pharmaceuticals Announces Election of Jennifer Good to its Board of Directors

BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the election of Jennifer Good to its Board of D…
Show more

Rhythm Pharmaceuticals Blogs

Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome

BOSTON , March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S.

Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference Content Import Tue, 02/25/2020 - 08:00 Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference February 25, 2020 at 8:00 AM EST This release…

Rhythm Pharmaceuticals Announces Leadership Transition

Rhythm Pharmaceuticals Announces Leadership Transition Content Import Mon, 01/06/2020 - 16:16 Rhythm Pharmaceuticals Announces Leadership Transition January 6, 2020 at 4:15 PM EST This release is a backfill from a News Wire General Ke…

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes Content Import Thu, 12/05/2019 - 08:01 Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating S…

Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference

Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference Content Import Wed, 11/13/2019 - 08:02 Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference November 13, 2019 at 8:01 AM EST This release is a backfill from a News Wire …

Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019

-- Data show treatment effect of setmelanotide on additional secondary endpoints, including body mass index --  -- Additional safety analyses show no significant increases in heart rate or blood pressure -- -- Two oral presentations delivered today during special research forum; poster
Show more

Rhythm Pharmaceuticals Frequently Asked Questions

  • When was Rhythm Pharmaceuticals founded?

    Rhythm Pharmaceuticals was founded in 2008.

  • Who are Rhythm Pharmaceuticals key executives?

    Rhythm Pharmaceuticals's key executives are Nithya Desikan, Simon D. Kelner and Hunter Smith.

  • How many employees does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 22 employees.

  • Who are Rhythm Pharmaceuticals competitors?

    Competitors of Rhythm Pharmaceuticals include Aimmune Therapeutics, Ampio Pharmaceuticals and Genprex.

  • Where is Rhythm Pharmaceuticals headquarters?

    Rhythm Pharmaceuticals headquarters is located at 222 Berkeley St 12th floor, Boston.

  • Where are Rhythm Pharmaceuticals offices?

    Rhythm Pharmaceuticals has an office in Boston.

  • How many offices does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 1 office.